Tekmira Pharmaceuticals this week reported a jump in its second-quarter net loss as revenues shrank and expenses increased.

For the three-month period ended June 30, Tekmira's net loss rose to $4.2 million from $2.3 million in the same period a year earlier.

Contributing to the higher loss was a decline in revenues to $2.3 million from $3.8 million, which the company attributed to fluctuations in demand for its manufacturing services and the timing of milestone payments from collaborators.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.